MR重T2W首次通过灌注成像鉴别乳腺良恶性肿瘤的价值初探

目的　评价在同 1次检查中T1W动态增强成像之后进行重T2 W (T 2 W )首次通过灌注成像的可行性 ,以及后者在鉴别乳腺良恶性肿瘤方面的诊断价值。方法　 2 9例乳腺病患者在T1W动态增强后进一步行病灶局部的T 2 W首次通过灌注成像 ,分别根据病灶T1W动态增强的早期强化程度和T 2 W首次通过灌注成像的早期信号丢失程度判定病灶的良恶性 ,计算其敏感度、特异度 ,以进行两方法间的比较。结果　应用T1W动态增强成像序列 ,良、恶性病变的信号强度增加率之间差异有显著性意义 (t=2 5 6 3,P =0 0 16 ) ,但两者的早期增强程度范围有很大的重叠 ;早期增强率诊断的敏感度为 94 % ,特异度仅为 2 5 %。应用T 2 W首次通过灌注成像序列 ,良、恶性病变之间的T2 信号强度丢失程度差异有非常显著性意义 (t=4 777,P <0 0 0 1) ,良、恶性病变的早期信号丢失率之间重叠很少 ;早期信号丢失率诊断的敏感度为 88% ,特异度为 75 %。结论　T 2 W首次通过灌注成像在鉴别良恶性乳腺肿瘤方面具有较高特异度 ;在同一患者中 ,T 2 W首次通过灌注成像结合T1W动态增强成像检查是可行的 ,可以提高乳腺MR成像的诊断准确性。     

Multi-section magnetic susceptibility perfusion echo-planar imaging of the breast

PURPOSE: To examine the diagnostic value of multi-section magnetic susceptibility perfusion echo-planar imaging (perfusion EPI) in patients with breast tumors prior to T1-weighted dynamic MRI. MATERIALS AND METHODS: MR imaging was performed in 75 patients with pathologically proved breast tumors using a 1.5 Tesla MR unit (MAGNETOM Symphony, Siemens Medical Solutions, Erlangen, Germany). Perfusion EPI was carried out before, during, and after the bolus injection of 0.1 mmol Gd-DTPA/kg. Two patients had two carcinomas in the same breast, one patient had both a benign and a malignant lesion in the same breast, and two patients had lesions in both breasts. Histopathological diagnosis was non-invasive ductal carcinoma in 9, invasive carcinoma in 49, and benign lesion in 22. The first-pass signal intensity loss of the lesions was calculated by perfusion EPI. RESULTS: Fifty-one of 58 carcinomas but only 4 of 22 benign lesions had a signal intensity loss of 20% or more during the first pass, for a sensitivity of 88% and specificity of 82% CONCLUSION: Perfusion EPI can be used as a useful diagnostic tool for differentiation between benign and malignant lesions. It is also thought to be a promising method for diagnosing multifocal breast lesions.     

Dynamic contrast-enhanced T2*-weighted MR imaging of tumefactive demyelinating lesions.

PURPOSE: Dynamic contrast-enhanced T2*-weighted MR imaging has been helpful in characterizing intracranial mass lesions by providing information on vascularity. Tumefactive demyelinating lesions (TDLs) can mimic intracranial neoplasms on conventional MR images, can be difficult to diagnose, and often result in surgical biopsy for suspected tumor. The purpose of this study was to determine whether dynamic contrast-enhanced T2*-weighted MR imaging can be used to distinguish between TDLs and intracranial neoplasms that share common features on conventional MR images. METHODS: We retrospectively reviewed the conventional and dynamic contrast-enhanced T2*-weighted MR images and medical records of 10 patients with tumefactive demyelinating disease that was diagnosed by either biopsy or strong clinical suspicion supported by laboratory evaluation that included CSF analysis and evoked potential tests. Twelve TDLs in 10 patients and 11 brain tumors that appeared similar on conventional MR images were studied. Relative cerebral blood volume (rCBV) was calculated from dynamic MR data and was expressed as a ratio to contralateral normal white matter. rCBV values from 11 patients with intracranial neoplasms with very similar conventional MR imaging features were used for comparison. RESULTS: The rCBV values of TDLs ranged from 0.22 to 1.79 (n = 12), with a mean of 0.88 +/- 0.46 (SD). The rCBV values of intracranial neoplasms ranged from 1.55 to 19.20 (n = 11), with a mean of 6.47 +/- 6.52. The difference in rCBV values between the two groups was statistically significant (P =.009). The difference in rCBV values between TDLs and primary cerebral lymphomas (n = 4) was less pronounced but was statistically significant (P =.005). CONCLUSION: Dynamic contrast-enhanced T2*-weighted MR imaging is a useful diagnostic tool in differentiating TDLs from intracranial neoplasms and may therefore obviate unnecessary surgical biopsy.     

乳腺MR灌注时间-信号强度曲线表现及价值研究

目的探讨乳腺MRT2*WI首次通过灌注时间-信号强度曲线(TIC)表现及其在乳腺病变鉴别诊断中的价值。资料与方法对40例乳腺肿瘤患者行乳腺动态增强成像扫描,绘制T2*WI首次通过灌注TIC及T1WI动态增强TIC。采用Fisher’s确切概率法检验,判定良、恶性病灶T1WI动态增强及灌注TIC的差异。结果良、恶性病灶灌注TIC之间差异具有显著性统计学意义(P<0.05=0.000);良、恶性病灶T1WI动态增强TIC之间差异有显著性统计学意义(P<0.05=0.011),但在平台型曲线类型中良恶性病灶有较大重叠。结论乳腺MR灌注TIC在良、恶性病灶具有显著差别,恶性病灶灌注TIC主要表现为信号快速下降后缓慢回升(A型)与快速下降后不回升(B型);良性病灶灌注TIC主要表现为平直型(C型)及缓慢上升后平台型(D型)。灌注TIC与病灶形态学结合可大大提高乳腺疾病诊断的准确性。     

T2-weighted MR imaging in the assessment of cirrhotic liver

PURPOSE: To assess if T2-weighted magnetic resonance (MR) imaging provides added diagnostic value in combination with dynamic gadolinium-enhanced MR imaging in the detection and characterization of nodular lesions in cirrhotic liver. MATERIALS AND METHODS: Two readers retrospectively and independently analyzed 54 MR imaging studies in 52 patients with cirrhosis. In session 1, readers reviewed T1-weighted and dynamic gadolinium-enhanced images. In session 2, readers reviewed T1-weighted, dynamic gadolinium-enhanced, and respiratory-triggered T2-weighted fast spin-echo images. Readers identified and characterized all focal lesions by using a scale of 1-4 (1, definitely benign; 4, definitely malignant). Multireader correlated receiver operating characteristic (ROC) analysis was employed to assess radiologist performance in session 2 compared with session 1. The difference in the areas under the ROC curves for the two sessions was tested. In a third session, readers assessed conspicuity of biopsy-proved lesions on T2-weighted MR images by using a scale of 1-3 (1, not seen; 3, well seen) and identified causes of reduced conspicuity. RESULTS: Two additional benign lesions were detected by each reader in session 2. Fifty-five lesions had pathologic verification, including 32 malignant, three high-grade dysplastic, and 20 benign nodules. There was no significant difference in the area under the ROC curves between the two sessions (P =.48). Thirty-two lesions were inconspicuous on T2-weighted MR images because of parenchymal heterogeneity, breathing artifacts (particularly in patients with ascites), and lesion isointensity with liver parenchyma. T2-weighted MR imaging was useful in the evaluation of cysts and lymph nodes. CONCLUSION: T2-weighted MR imaging does not provide added diagnostic value in the detection and characterization of focal lesions in cirrhotic liver.     

Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging.

PURPOSE: To evaluate the role of T2*-weighted echo-planar perfusion imaging by using a first-pass gadopentetate dimeglumine technique to determine the association of magnetic resonance (MR) imaging-derived cerebral blood volume (CBV) maps with histopathologic grading of astrocytomas and to improve the accuracy of targeting of stereotactic biopsy. MATERIALS AND METHODS: MR imaging was performed in 29 patients by using a first-pass gadopentetate dimeglumine T2*-weighted echo-planar perfusion sequence followed by conventional imaging. The perfusion data were processed to obtain a color map of relative regional CBV. This information formed the basis for targeting the stereotactic biopsy. Relative CBV values were computed with a nondiffusible tracer model. The relative CBV of lesions was expressed as a percentage of the relative CBV of normal white matter. The maximum relative CBV of each lesion was correlated with the histopathologic grading of astrocytomas obtained from samples from stereotactic biopsy or volumetric resection. RESULTS: The maximum relative CBV in high-grade astrocytomas (n = 26) varied from 1.73 to 13.7, with a mean of 5.07 +/- 2.79 (+/- SD), and in the low-grade cohort (n = 3) varied from 0.92 to 2.19, with a mean of 1.44 +/- 0.68. This difference in relative CBV was statistically significant (P < .001; Student t test). CONCLUSION: Echo-planar perfusion imaging is useful in the preoperative assessment of tumor grade and in providing diagnostic information not available with conventional MR imaging. The areas of perfusion abnormality are invaluable in the precise targeting of the stereotactic biopsy.     

乳腺肿瘤MRI序列联合运用与微血管密度的对照研究

目的：探讨同一次检查中T2WI首次通过灌注成像及T1WI动态增强成像的联合应用在鉴别乳腺良恶性肿瘤方面的价值,并对所有病灶进行免疫组化CD34染色计数微血管密度进行评分,评价其相关性。方法：37例乳腺患者经手术或穿刺病理证实分为良恶性两组,经过MRIT2WI首次通过灌注成像后进一步行T1WI动态增强成像,对灌注及动态增强各参数进行分析,并与手术后病理图像及免疫组化结果对照。结果：乳腺肿块37例,乳腺癌21例,乳腺良性病灶16例,应用T2WI首过灌注成像,良恶性组早期信号强度丢失率之间重叠很少,敏感性为90%,特异性为75%;较T1WI动态增强组（敏感性47.6%,特异性为68.7%）提高;恶性组最大信号强度下降率与微血管密度MVD有明显正相关性（r=0.502,P〈0.05）,最大信号强度下降时间与微血管密度无明显相关性。良性组最大信号强度下降率、最大信号强度下降时间与微血管密度均无明显相关性。结论：乳腺癌T2WI灌注成像表现与病理特征相符,在乳腺癌血管生成的评价方面有重要价值。联合T2WI首次通过灌注成像及T1WI动态增强成像能够提高乳腺肿瘤的诊断特异性。     

Dynamic contrast-enhanced T2*-weighted MR imaging of gliomatosis cerebri

BACKGROUND AND PURPOSE: MR imaging characteristics of gliomatosis cerebri reiterate the diffuse nature of this tumor but are nonspecific and thus may pose a diagnostic challenge. Because perfusion MR imaging can provide a physiologic map of the microcirculation, we compared the measured relative cerebral blood volume (rCBV) at perfusion imaging with histopathologic findings in gliomatosis cerebri. MR spectroscopic findings were also reviewed. METHODS: Retrospective analysis was performed of conventional and perfusion MR images from seven patients with proved gliomatosis cerebri. The conventional MR images were evaluated for the presence or absence of contrast enhancement, necrosis, and extent of T2-weighted signal intensity abnormality. Dynamic contrast-enhanced T2*-weighted gradient-echo echo-planar images were acquired during the first pass of a bolus injection of gadopentetate dimeglumine. The rCBV was calculated by using nondiffusible tracer kinetics and expressed relative to normal-appearing white matter. Pathologic findings were reviewed in all patients and compared with the MR perfusion data. Multivoxel 2D chemical shift imaging proton MR spectroscopic data were available for three patients and single-voxel data for one patient. RESULTS: Conventional MR images showed diffuse abnormality in all cases and absence of contrast enhancement in all but one case. Average rCBV range was 0.75-1.26 (mean, 1.02 +/- 0.42 [SD]). MR spectroscopic data revealed spectra consistent with presence of tumoral disease. Histopathologic review showed absence of vascular hyperplasia in all specimens. CONCLUSION: The low MR rCBV measurements of gliomatosis cerebri are in concordance with the lack of vascular hyperplasia found at histopathologic examination; thus, perfusion MR imaging provides useful adjunctive information that is not available from conventional MR imaging techniques.     

Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin

BACKGROUND AND PURPOSE: Dynamic, contrast-enhanced MR imaging has allowed quantitative assessment of cerebral blood volume (CBV) in brain tumors. The purpose of our study was to compare postcontrast T1-weighted imaging with dynamic, contrast-enhanced T2*-weighted echo-planar imaging in the evaluation of the response of recurrent malignant gliomas to thalidomide and carboplatin. METHODS: Serial MR imaging was performed in 18 consecutive patients with recurrent malignant gliomas receiving both thalidomide and carboplatin for 12-month periods. Six patients undergoing carboplatin therapy alone were chosen as control subjects. Conventional postcontrast T1-weighted images were compared with relative CBV (rCBV) maps calculated on a pixel-by-pixel basis from dynamic echo-planar imaging data. Tumor progression was evaluated clinically using established criteria for malignant gliomas. Studies were performed at 2- to 3-month intervals, and imaging and clinical findings were compared. RESULTS: Tumor response to treatment, based on clinical findings, did not correlate well with conventional imaging findings. The rCBV values decreased significantly in all patients between the start of therapy and the first follow-up in the study group, but not in the control group. The difference in rCBV values between the clinically stable and the progressive group at 12-month follow-up was statistically significant, with the progressive group having higher values. CONCLUSION: Dynamic, contrast-enhanced MR imaging is a valuable adjunct to conventional imaging in assessing tumor activity during antiangiogenic therapy, and correlates better than conventional studies with clinical status and response to therapy.     

Adrenal masses: characterization with T1-weighted MR imaging

The ability of a T1-weighted spin-echo magnetic resonance (MR) sequence to allow differentiation of benign from malignant adrenal masses at 0.5 T was investigated in 28 patients with 35 adrenal masses. All nine lesions with an adrenal mass-liver signal intensity ratio of 0.71 or less were metastases, and all 15 with a ratio of 0.78 or more were adenomas. Eleven masses (31%)--including six adenomas, three metastases, a pheochromocytoma, and a neuroblastoma--had ratios between these values. Nine of ten masses with adrenal mass-fat intensity ratios of 0.35 or less were metastases, and all 12 with ratios of 0.42 or more were benign. Eleven masses (31%), four malignant and one benign, had ratios between these values. The ratios for two masses could not be calculated due to lack of fat. The specificity of T1-weighted MR imaging in differentiating benign from malignant adrenal masses appears similar to that reported for T2-weighted imaging. However, significant overlap occurred, as has also been reported for T2-weighted imaging. While both imaging sequences may help distinguish benign from malignant adrenal masses in some cases, biopsy is still necessary when an accurate histologic diagnosis is essential.     

Dynamic contrast-enhanced MR imaging and MR-guided bone biopsy on a 0.23 T open imager

OBJECTIVE: To assess the feasibility of MR (magnetic resonance)-guided bone biopsies. DESIGN AND PATIENTS: Thirty-six consecutive patients with known or suspected benign or malignant bone lesions underwent comprehensive MR imaging. A dynamic contrast-enhanced sequence followed by stationary T1-weighted sequences were obtained and MR-guided bone biopsy of the tumor at the site with fastest enhancement was performed using an open 0.23 T MR imager. RESULTS: All MR-guided bone biopsies samples were estimated to be sufficient by the pathologists. The biopsy specimens were diagnostic in 34 of 36 cases. CONCLUSION: MR-guided bone biopsies combined with dynamic contrast-enhanced imaging are feasible and safe for the diagnostic investigation of equivocal bone lesions.     

软组织肿瘤的MR灌注成像与MR波谱成像的比较研究

目的 通过分析软组织肿瘤同一病例相同感兴趣区的MR灌注加权成像(MR-PWI)及MR氢质子波谱(1H-MRS)的功能影像信息,比较两者用于软组织肿瘤的定性诊断价值.方法 研究同时行MR-PWI、1H-MRS的全身各部位软组织肿瘤共40例.比较MR-PWI及1H-MRS各参数在良、恶性肿瘤中的差异,进而对2种诊断方法进行评价.所获数据采用t检验或配对四格表确切概率法分析.结果 MR-PWI良、恶性软组织肿瘤的血流量(BF)值差异有统计学意义(t=2.531,P<0.05),血容量(BV)及平均通过时间(MTT)值差异均无统计学意义(t值分别为1.587和1.732,P值均>0.05);以BF值=4.35 ml·100 mg-1·min-1为阈值,MR-PWI诊断恶性肿瘤的敏感度为81.8%(18/22),特异度为72.2%(13/18).良、恶性软组织肿瘤的时间信号曲线(TIC)类型比较:Ⅰ a型在良性肿瘤中占3/18,在恶性肿瘤中占17/22;Ⅰ b型在良性肿瘤中占12/18,在恶性肿瘤中占3/22;Ⅰ c型在恶性肿瘤中占2/22.Ⅱ型在良性肿瘤中占3/18.良、恶性软组织肿瘤的胆碱(Cho)、肌酸复合物(Cr)、脂质(Lip)值差异均无统计学意义(t值分别为1.332、1.637、1.986,P值均>0.05),而Cho/Cr比值的差异有统计学意义(t=2.927,P<0.05);以Cho/Cr比值=3.22为阈值,1H-MRS诊断恶性肿瘤的敏感度为86.4%(19/22),特异度为88.9%(16/18).1H-MRS谱线比较:18例良性及17例恶性软组织肿瘤在2.0～2.1ppm(×10-6)处均未出现异常峰,而2例恶性神经鞘瘤和3例恶性纤维组织细胞瘤均在2.0～2.1ppm处出现异常峰.MR-DWI与1H-MRS用于恶性肿瘤诊断准确度的差异无统计学意义(X2=0.125,P>0.05).结论 软组织肿瘤的MR-PWI的BF值、1H-MRS的Cho/Cr比值有利于软组织肿瘤良、恶性的鉴别;软组织肿瘤的TIC形态有助于肿瘤良、恶性的鉴别.MR-PWI和1H-MRS两者用于诊断恶性软组织肿瘤的准确度无明显差异,1H-MRS诊断恶性软组织肿瘤的敏感度和特异度较高.     

MR imaging of pelvic masses in women: contrast-enhanced vs unenhanced images.

OBJECTIVE. We compared the value of contrast-enhanced MR images with that of T2-weighted MR images in the diagnosis and staging of pelvic masses in women. MATERIALS AND METHODS. The findings on preoperative MR studies of 97 patients with a total of 124 surgically proved lesions were retrospectively analyzed. Unenhanced T1- and T2-weighted spin-echo images were compared with contrast-enhanced T1-weighted images. The final diagnosis included benign (36 patients), borderline (six patients), and malignant (15 patients) ovarian masses, fallopian tube masses (15 patients), endometrial tumors (seven patients), cervical carcinomas (32 patients), subserous leiomyomas (11 patients), and two masses of extragenital origin. RESULTS. In the depiction of pelvic lesions, the sensitivity of contrast-enhanced MR imaging (96%) was equal to that of unenhanced T2-weighted imaging (97%). Contrast-enhanced images were useful in the definition of intratumoral architecture and tumor borders of 72 adnexal masses, resulting in better determination of malignancy (accuracy, 95%) than on T2-weighted images (85%). Size of viable tumor, differentiation of tumor from retained fluid, and depth of myometrial invasion of six endometrial carcinomas were most reliably shown on contrast-enhanced images. In the evaluation of cervical carcinoma, overall staging accuracy of contrast-enhanced imaging (80%) was slightly inferior to that of T2-weighted imaging (83%). However, contrast-enhanced images improved assessment of parametrial and organ invasion in seven cases in which findings on T2-weighted MR images were equivocal. Administration of contrast material was not helpful in the evaluation of subserous leiomyomas or masses of extragenital origin. CONCLUSIONS. The findings suggest that when results of unenhanced T1- and T2-weighted MR imaging of pelvic masses are equivocal, contrast-enhanced MR images should be used as supportive and complementary pulse sequences to (1) improve definition of intratumoral architecture and prediction of malignancy in adnexal tumors, (2) stage endometrial carcinoma, and (3) determine tumor extension in cervical carcinoma.     

Hepatocellular carcinoma in the cirrhotic liver: gadolinium-enhanced 3D T1-weighted MR imaging as a stand-alone sequence for diagnosis

PURPOSE: To retrospectively assess the usefulness of contrast material-enhanced T1-weighted magnetic resonance (MR) imaging alone and with T2-weighted MR imaging in the diagnosis of hepatocellular carcinoma (HCC). MATERIALS AND METHODS: A waiver of informed consent and institutional review board approval for this retrospective study were granted. The study was HIPAA compliant. Twenty-eight men (mean age, 49 years; range, 23-70 years) and 10 women (mean age, 53 years; range, 42-72 years) with cirrhosis underwent T2-weighted and contrast-enhanced T1-weighted MR imaging at 1.5 T within 90 days of liver transplantation. Three readers reviewed the T1-weighted images alone and then the T2-weighted and T1-weighted images together. Lesion detection, characterization, and reader confidence levels were recorded. RESULTS: At liver explantation, 57 lesions were present in 18 patients: 19 HCCs, 33 dysplastic nodules, and five cysts. Contrast-enhanced T1-weighted imaging depicted 13 of 19 HCCs with an overall sensitivity of 68.4% (13 of 19) and specificity of 65.7% (23 of 35). The sensitivity and specificity for detection of dysplastic nodules (sensitivity, 9%; specificity, 68.4%) and HCCs (sensitivity, 68.4%; specificity, 65.7%) were nearly identical for T1-weighted images read alone or read with T2-weighted images. The only difference was the specificity for T1-weighted images read alone (65.7%) and read with T2-weighted images (62.9%). The addition of T2-weighted images altered the diagnosis in one of 90 (1.1%) cases and provided an increase in diagnostic confidence in four of 258 (1.6%) cases for independent readers and three of 90 (3.3%) cases at consensus reading. CONCLUSION: Contrast-enhanced T1-weighted imaging can be used as a stand-alone sequence for the diagnosis of HCC in patients with cirrhosis prior to liver transplantation.     

The role of diffusion-weighted imaging and the apparent diffusion coefficient (ADC) values for breast tumors.

OBJECTIVE: We wanted to evaluate the role of diffusion-weighted imaging (DWI) and the apparent diffusion coefficient (ADC) for detecting breast tumors, as compared with the T1- and T2-weighted images. MATERIALS AND METHODS: Forty-one female patients underwent breast MRI, and this included the T1-, T2-, DWI and dynamic contrast-enhanced images. Sixty-five enhancing lesions were detected on the dynamic contrast-enhanced images and we used this as a reference image for detecting tumor. Fifty-six breast lesions were detected on DWI and the histological diagnoses were as follows: 43 invasive ductal carcinomas, one mucinous carcinoma, one mixed infiltrative and mucinous carcinoma, seven ductal carcinomas in situ (DCIS), and four benign tumors. First, we compared the detectability of breast lesions on DWI with that of the T1- and T2-weighted images. We then compared the ADCs of the malignant and benign breast lesions to the ADCs of the normal fibroglandular tissue. RESULTS: Fifty-six lesions were detected via DWI (detectability of 86.2%). The detectabilities of breast lesions on the T1- and T2-weighted imaging were 61.5% (40/65) and 75.4% (49/65), respectively. The mean ADCs of the invasive ductal carcinoma (0.89+/-0.18 x 10(-3)mm(2)/second) and DCIS (1.17+/-0.18 x 10(-3)mm(2)/ second) are significantly lower than those of the benign lesions (1.41+/-0.56 x 10(-3)mm(2)/second) and the normal fibroglandular tissue (1.51+/-0.29 x 10(-3)mm(2)/ second). CONCLUSION: DWI has a high sensitivity for detecting breast tumors, and especially for detecting malignant breast tumors. DWI was an effective imaging technique for detecting breast lesions, as compared to using the T1- and T2-weighted images.     

Gadolinium-enhanced MR imaging, T2-weighted MR imaging, and transurethral ultrasonography

PURPOSE: To assess the value and problems of dynamic gadolinium-enhanced MR imaging, T2-weighted MR imaging, and transurethral ultrasonography(TUUS) in staging of urinary bladder cancer. MATERIALS AND METHODS: Dynamic gadolinium-enhanced MR imaging and FSE T2-weighted MR imaging of 64 patients with urinary bladder cancer who subsequently had surgery were retrospectively reviewed and compared with TUUS findings. RESULTS: Specificity for muscular invasion was 90.5% with TUUS, significantly better than with dynamic MR imaging (64.9%) (p < 0.05). The rates of overestimation of superficial cancer(pT1) with dynamic MRI and T2-weighted MR imaging were 35.1%(13/37) and 24.3%(9/37), respectively. The staging accuracy of invasive cancer(pT2 or over) was 85.2% with dynamic MR imaging, which was better than the rate of 75.0% achieved with T2-weighted MR imaging. CONCLUSION: Although TUUS was a better modality for diagnosing superficial cancer(pT1), dynamic MR imaging was found to be better for diagnosing invasive(pT2 or over) cancer.     

Assessment of hemorrhage in pituitary macroadenoma by T2*-weighted gradient-echo MR imaging

BACKGROUND AND PURPOSE: Intratumoral hemorrhage occurs frequently in pituitary macroadenoma and manifests as pituitary apoplexy and recent or old silent hemorrhage. T2*-weighted gradient-echo (GE) MR imaging is the most sensitive sequence for the detection of acute and old intracranial hemorrhage. T2*-weighted GE MR imaging was used to investigate intratumoral hemorrhage in pituitary macroadenomas. MATERIALS AND METHODS: Twenty-five consecutive patients who underwent total or subtotal resection of pituitary macroadenoma with heights from 17 to 53 mm, including 1 patient with classic pituitary apoplexy, underwent MR imaging before surgery, including T2*-weighted GE MR imaging. For histologic assessment of the hemorrhage in whole surgical specimens, we used hematoxylin-eosin staining. RESULTS: T2*-weighted GE MR imaging detected various types of dark lesions, such as "rim," "mass," "spot," and "diffuse" and combinations, indicating clinical and subclinical intratumoral hemorrhage in 12 of the 25 patients. The presence of intratumoral dark lesions on T2*-weighted GE MR imaging correlated significantly with the hemorrhagic findings on T1- and T2-weighted MR imaging (P < .02 and <.01, respectively), and the surgical and histologic hemorrhagic findings (P < .001 and <.001, respectively). CONCLUSION: T2*-weighted GE MR imaging could detect intratumoral hemorrhage in pituitary adenomas as various dark appearances. Therefore, this technique might be useful for the assessment of recent and old intratumoral hemorrhagic events in patients with pituitary macroadenomas.     

Breast carcinoma: effect of preoperative contrast-enhanced MR imaging on the therapeutic approach

PURPOSE: To determine if magnetic resonance (MR) imaging can help determine the therapeutic approach in women with breast cancer. MATERIALS AND METHODS: Preoperative contrast-enhanced MR imaging of the breast was performed in 463 patients with probably benign lesions (n = 63), suspicious lesions (n = 230), or lesions highly suggestive of malignancy (n = 170) per established clinical, mammographic, and/or ultrasonographic (US) criteria. T1-weighted fast low-angle shot MR imaging was performed before and after administration of gadopenetetate dimeglumine. MR imaging findings were correlated with other imaging results and histopathologic findings. Special attention was paid to multifocality and multicentricity. RESULTS: Histopathologic analysis revealed 143 benign and 405 malignant lesions. The sensitivity, specificity, and accuracy were 58%, 76%, and 62% for clinical examination; 86%, 32%, and 72% for conventional mammography; 75%, 80%, and 76% for US; and 93%, 65%, and 85% for contrast-enhanced MR imaging. Multifocality in 30 of 42 patients, multicentricity in 24 of 50 patients, and additional contralateral carcinomas in 15 of 19 patients were depicted with MR imaging alone. Due to the MR imaging findings, therapy was changed correctly in 66 patients (14.3%); unnecessary open biopsy was performed in 16 patients (3.5%). CONCLUSION: Contrast-enhanced MR imaging of the breast is highly sensitive for invasive breast cancer. MR imaging may reveal unsuspected multifocal, multicentric, or contralateral breast carcinoma and result in therapy changes.     

Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging--initial results

PURPOSE: To prospectively compare the sensitivity and specificity of high-spatial-resolution dynamic contrast material-enhanced magnetic resonance (MR) imaging with those of high-spatial-resolution T2-weighted MR imaging, performed with an endorectal coil (ERC), for assessment of extracapsular extension (ECE) and staging in patients with prostate cancer, with histopathologic findings as reference. MATERIALS AND METHODS: The study was approved by the institutional internal review board; a signed informed consent was obtained. MR imaging of the prostate at 1.5 T was performed with combined surface coils and ERCs in 32 patients (mean age, 65 years; range, 42-78 years) before radical prostatectomy. High-spatial-resolution T2-weighted fast spin-echo and high-spatial-resolution dynamic contrast-enhanced three-dimensional gradient-echo images were acquired with gadopentetate dimeglumine. Dynamic contrast-enhanced MR images were analyzed with a computer-generated color-coded scheme. Two experienced readers independently assessed ECE and tumor stage. MR imaging-based staging results were compared with histopathologic results. For the prediction of ECE, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated. Staging accuracy was determined with the area under the receiver operating characteristic curve (AUC) by using the Wilcoxon-Mann-Whitney index of diagnostic accuracy. RESULTS: The mean sensitivity, specificity, PPV, and NPV for assessment of ECE with the combined data sets for both readers were 86%, 95%, 90%, and 93%, respectively. The sensitivity of MR images for determination of ECE was significantly improved for both readers (>25%) with combined data sets compared with T2-weighted MR images alone. The combined data sets had a mean overall staging accuracy for both readers of 95%, as determined with AUC. Staging results for both readers were significantly improved (P<.05) with the combined data sets compared with T2-weighted MR images alone. CONCLUSION: The combination of high-spatial-resolution dynamic contrast-enhanced MR imaging and T2-weighted MR imaging yields improved assessment of ECE and better results for prostate cancer staging compared with either technique independently.     

Improved tissue characterization of focal liver lesions with ferumoxide-enhanced T1 and T2-weighted MR imaging

The purpose of our study was to evaluate the potential value of ferumoxide-enhanced T1-weighted magnetic resonance (MR) imaging for tissue characterization of focal liver lesions when combined with T2-weighted sequences. Images were acquired within 30 minutes after the end of ferumoxide administration, when ferrite particles were not totally cleared from the intravascular compartment. Thirty-eight patients with 47 focal liver lesions underwent T1-weighted gradient-echo (TR/TE 150/4.1 msec) and T2-weighted fast spin-echo (3180-8638/90 msec) MR imaging at 1.5 T before and after intravenous administration of ferumoxides (10 micromol/kg body weight). A qualitative and quantitative analysis was performed. During the early phase after infusion of ferumoxide, blood vessels showed hypersignal intensity on T1-weighted fast low-angle shot (FLASH) images, while liver signal decreased. Hemangiomas showed both homogeneous and inhomogeneous enhancement patterns, and liver metastasis most typically showed ring enhancement. Hypervascular tumors (hepatocellular carcinomas and focal nodular hyperplasias) showed a slight degree of homogeneous enhancement. Quantitatively, the degree of enhancement and lesion-to-liver contrast on ferumoxide-enhanced images were significantly different among these tumors. Our results demonstrate that distinct enhancement patterns obtained on ferumoxide-enhanced T1-weighted MR imaging improve tissue characterization of focal liver lesions when combined with T2-weighted images.